Nieuws
Superluminal to receive payments, equity investment, royalties Lilly, Novo pursuing GPCR-targeting drugs for obesity Superluminal's lead candidate not part of deal with Lilly Aug 14 (Reuters) - Eli ...
Eli Lilly and Co LLY has entered into a $1.3 billion deal with Superluminal Medicines to develop small-molecule drugs through artificial intelligence (AI) to treat obesity and other cardiometabolic ...
Gehost op MSN1mnd
Lilly signs $1.3 billion deal with Superluminal to discover obesity medicines using AI
(Reuters) -Eli Lilly has signed a deal worth $1.3 billion with privately held Superluminal Medicines to discover and develop small-molecule drugs through AI to treat obesity and other cardiometabolic ...
Sommige resultaten zijn verborgen omdat ze mogelijk niet toegankelijk zijn voor u.
Niet-toegankelijke resultaten weergeven
Feedback